267 related articles for article (PubMed ID: 9476567)
21. [Role of GP IIb/IIIa blockers in clinical cardiology].
Rossi ML; Merlini PA
Recenti Prog Med; 2003 Oct; 94(10):440-3. PubMed ID: 14619191
[TBL] [Abstract][Full Text] [Related]
22. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
[TBL] [Abstract][Full Text] [Related]
23. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Tcheng JE
Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
[No Abstract] [Full Text] [Related]
24. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
25. [Modern "antiplatelet agents" in unstable angina].
Vahanian A; Garbarz E
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1521-6. PubMed ID: 9092413
[TBL] [Abstract][Full Text] [Related]
26. [Glycoprotein IIb/IIIa antagonists].
Hennemann A
Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
[No Abstract] [Full Text] [Related]
27. The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.
Koller CF
Heart Lung; 2001; 30(5):321-9; quiz 330-1. PubMed ID: 11604974
[TBL] [Abstract][Full Text] [Related]
28. [Monoclonal antibodies in cardiology].
Legrand V
Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465
[TBL] [Abstract][Full Text] [Related]
29. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
[TBL] [Abstract][Full Text] [Related]
30. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
Gambhir DS; Mukhopadhyay S
Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
[No Abstract] [Full Text] [Related]
31. Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.
Tcheng JE
Tex Heart Inst J; 1998; 25(1):49-56. PubMed ID: 9566064
[TBL] [Abstract][Full Text] [Related]
32. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Teirstein PS; Kao J; Watkins M; Tannenbaum MA; Laufer N; Chang M; Mehran R; Dangas G; Russell ME; Ellis SG; Stone GW
Am J Cardiol; 2005 Aug; 96(4):500-5. PubMed ID: 16098300
[TBL] [Abstract][Full Text] [Related]
33. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
34. Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies.
SoRelle R
Circulation; 2002 Jan; 105(3):E9067-8. PubMed ID: 11826859
[No Abstract] [Full Text] [Related]
35. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
Rossi ML; Merlini PA
Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
[No Abstract] [Full Text] [Related]
36. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
Boersma E
J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
[No Abstract] [Full Text] [Related]
37. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
38. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Mehta SR;
J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
[TBL] [Abstract][Full Text] [Related]
39. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
Albuquerque A
Rev Port Cardiol; 2001 Sep; 20(9):927-8. PubMed ID: 11763604
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
